Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by an increase in BAFF
(BLyS) levels and a resulting B cell hyperactivity. B cells are involved in the pathogenesis
of SS in both systemic and glandular features, and B cell downregulation may lead to a
decrease of disease activity. Moreover, pathogenesis of SS is closed to that of Systemic
lupus erythematosus, where Belimumab has been proven to be effective.